← FDA DRUG APPROVALS

FDA ANDA · ANDA212688

LEVETIRACETAM EXTENDED-RELEASE

levetiracetam

Sponsor: OVERSEAS

APPLICATION
ANDA212688
TYPE
ANDA
ORIGINAL APPROVAL
2020-06-11
LATEST ACTION
2022-07-20
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

LEVETIRACETAMPrescription
LEVETIRACETAM 500MG · TABLET, EXTENDED RELEASE · ORAL
LEVETIRACETAMPrescription
LEVETIRACETAM 750MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-07-20Labeling · Supplement 2 · standardAP
2020-06-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →